• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. The company is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom.
Market Cap | 531.753 Million | Shares Outstanding | 32.743 Million | Avg 30-day Volume | 143.554 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -3.47 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -126.705 Million |
Price to Book Value | 0.0 | Operating Margin | 0.0 | Enterprise Value | 419.032 Million |
Current Ratio | 2.128 | EPS Growth | 0 | Quick Ratio | 1.763 |
1 Yr BETA | 0.6506 | 52-week High/Low | 0.0 / | Profit Margin | 0.0 |
Operating Cash Flow Growth | -26.7132 | Altman Z-Score | -7.7836 | Free Cash Flow to Firm | 0 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
No longer subject to file | 2021-03-29 | 0 | |
BANSAL AJAY SEE REMARKS |
|
No longer subject to file | 2021-03-29 | 0 |
OCAMPO CHRISTINE PAO; CAO/UROVANT SCIENCES,INC. |
|
No longer subject to file | 2021-03-29 | 0 |
|
No longer subject to file | 2021-03-29 | 0 | |
|
No longer subject to file | 2021-03-29 | 0 | |
ROBINSON JAMES A. JR. PEO;CEO/UROVANT SCIENCES, INC. |
|
No longer subject to file | 2021-03-29 | 0 |
SMITH BRYAN E. GC/UROVANT SCIENCES, INC. |
|
No longer subject to file | 2021-03-29 | 0 |
|
No longer subject to file | 2021-03-29 | 0 | |
HAAG-MOLKENTELLER CORNELIA CMO/UROVANT SCIENCES, INC. |
|
No longer subject to file | 2021-03-29 | 0 |
JOHNSTON WALT SEE REMARKS |
|
No longer subject to file | 2021-03-29 | 0 |
KATKIN KEITH PEO;CEO/UROVANT SCIENCES, INC. |
|
199,680 | 2020-02-19 | 0 |
|
22,963,263 | 2020-02-19 | 0 | |
|
No longer subject to file | 2019-12-27 | 0 | |
|
0 | 2019-12-27 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC |
|
No longer subject to file | 2019-07-10 | 0 |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
|
0 | 2019-07-09 | 0 | |
EBERSOLE NORI SVP;CHRO/UROVANT SCIENCES, INC |
|
0 | 2019-01-06 | 0 |
MCFADDEN MICHAEL E. CCO/UROVANT SCIENCES, INC. |
|
0 | 2019-01-06 | 0 |
|
22,703,669 | 2019-01-01 | 0 | |
|
0 | 2018-11-21 | 0 | |
|
22,703,669 | 2018-10-01 | 0 | |
|
22,703,669 | 2018-10-01 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
UROVANT SCIENCES LTD UROV | 2021-03-29 19:15:03 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-29 18:45:02 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-29 18:15:02 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-29 17:45:03 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-29 17:15:03 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-29 16:45:03 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-29 16:15:02 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-29 15:45:03 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-29 15:15:03 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-29 14:45:03 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-29 14:15:03 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-29 13:45:03 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-29 13:15:03 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-29 12:45:03 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-26 22:15:03 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-26 21:45:03 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-26 21:15:03 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-26 20:45:02 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-26 20:15:04 UTC | -3.1537 | 3.2237 | 400000 |
UROVANT SCIENCES LTD UROV | 2021-03-26 19:45:03 UTC | -3.1537 | 3.2237 | 400000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|